Evidence map›Paper›PMID 38410708›Full record

ArticleERJ open research2024

ERS International Congress 2023: highlights from the Thoracic Oncology Assembly.

Maria Joana Catarata, Andrew W Creamer, Margarida Dias, Sile Toland, Malek Chaabouni, Koen Verbeke, Joana Vieira Naia, Maged Hassan, Sindhu Bhaarrati Naidu, Geraldine A Lynch and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 7 countries.

Maria Joana CatarataPulmonology Department, Hospital de Braga, Braga, Portugal.
Andrew W CreamerGreat Western Hospitals NHS Foundation Trust, Swindon, UK.ORCID https://orcid.org/0000-0002-9314-1210
Margarida DiasPulmonology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Sile TolandDepartment of Medicine, Letterkenny University Hospital, Letterkenny, Ireland.
Malek ChaabouniAsklepios Klinik Altona, Department of Internal Medicine II, Pulmonology and Thoracic Oncology Section, Hamburg, Germany.
Koen VerbekeDepartment of Respiratory Medicine, University Hospital Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Joana Vieira NaiaPulmonology Department, Hospital de Braga, Braga, Portugal.
Maged HassanChest Diseases Department, Alexandria University Faculty of Medicine, Alexandria, Egypt.ORCID https://orcid.org/0000-0002-8768-6548
Sindhu Bhaarrati NaiduDepartment of Respiratory Medicine, University College London, London, UK.ORCID https://orcid.org/0000-0002-1106-6545
Geraldine A LynchAcademic Respiratory Unit, University of Bristol Medical School, Bristol, UK.ORCID https://orcid.org/0009-0007-6591-2720
Kevin G BlythQueen Elizabeth University Hospital, Glasgow, UK.ORCID https://orcid.org/0000-0003-2972-6641
Najib M RahmanOxford University Hospitals NHS Foundation Trust, Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Headington, UK.
Georgia Hardavella9th Department of Respiratory Medicine, Sotiria Athens Chest Diseases Hospital, Athens, Greece.
Hospital Braga · PTAlexandria University · EGAsklepios Klinik Altona · DECentro Hospitalar de Vila Nova de Gaia · PTGreat Western Hospitals NHS Foundation Trust · GBJohn Radcliffe Hospital · GBLetterkenny University Hospital · IEQueen Elizabeth University Hospital · GBSotiria General Hospital · GRUniversité Libre de Bruxelles · BEUniversity College London · GBUniversity of Bristol · GB

Funding

Marie Curie MCCC-RP-14-A17178Medical Research Council G0600475Medical Research Council G1001128
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer mortality in the world. It greatly affects the patients' quality of life, and is thus a challenge for the daily practice in respiratory medicine. Advances in the genetic knowledge of thoracic tumours' mutational landscape, and the development of targeted therapies and immune checkpoint inhibitors, have led to a paradigm shift in the treatment of lung cancer and pleural mesothelioma. During the 2023 European Respiratory Society Congress in Milan, Italy, experts from all over the world presented their high-quality research and reviewed best clinical practices. Lung cancer screening, management of early stages of lung cancer, application of artificial intelligence and biomarkers were discussed and they will be summarised here.

Identifiers

PMID38410708
PMCPMC10895436
OpenAlexW4389180580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.